Eli Lilly & Co. vs. XBiotech Inc
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| LLY | XBIT | |
|---|---|---|
| Market Cap | $1.12 trillion | $69.51 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-45,133,000 |
LLY leads on 2 of 2 size & scale factors.
Valuation
| LLY | XBIT | |
|---|---|---|
| P/E Ratio | 42.14 | — |
| Price / Book | 33.03 | 0.54 |
| Price / Sales | 14.05 | — |
XBIT leads on 1 of 1 valuation factors.
Profitability
| LLY | XBIT | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | -35.13% |
LLY leads on 1 of 1 profitability factors.
Dividend
| LLY | XBIT | |
|---|---|---|
| Dividend Yield | 0.55% | — |
| Payout Ratio | 23.23 | — |
LLY and XBIT split the dividend factors evenly.
Risk & Sentiment
| LLY | XBIT | |
|---|---|---|
| Short Interest | 1.29% | 17.67% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, XBIT overview, XBIT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.